CELL EXPANSION MARKET ANALYSIS

Cell expansion is the large scale artificial production of daughter cells from a single cell, to support medical research. Cell expansion requires the synthesis of new cell wall material and controlled loosening of the wall to allow it to stretch and increase in area. Cell expansion is used for life science related research and development, drug screening, drug development, etc.

• Cell expansion market is expected to grow as there is increasing R&D activities for the use of cell therapy technique for the development of vaccines, antibiotics, and therapeutics by the key market players.
• Cell expansion is used for various applications such as for the treatment of various diseases such as cancer, diabetes, etc.

Global Cell Expansion Market - Impact of the Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic is expected to hamper the growth of the global cell expansion market, owing to restriction in the supply chain of drugs during the COVID-19 pandemic. For instance, according to data reported by United Nations Office on Drugs and Crime in July 2020, the effective measures taken to control the spread of COVID-19 pandemic has at the end badly affected to drug supply chain. Many countries across the world have reported an overall shortage of many types of drugs at the retail level. Supply chain affected the transport and production of all kind of drugs, which is expected to hamper the market of acute bacterial skin and skin structure infections.

The coronavirus (COVID-19) pandemic and consequent lockdown in various countries across the globe have impacted the financial status of businesses in healthcare sectors. Players operating in the global cell expansion market are facing major challenges on various fronts due to the COVID-19 pandemic. The major challenges include supply of raw materials required for manufacturing instruments and accessories used in cell expansion applications along with irregularities in transportation facility.

Global cell expansion market is estimated to be valued at USD 19.69 Bn in 2024 and is expected to exhibit a CAGR of 11.8% during the forecast period (2024-2031).

Figure 1. Global Cell Expansion Market Value (US$ Bn), by Region, 2024

To learn more about this report, request a free sample copy

Development of new technologies in cell expansion is expected to offer lucrative growth opportunities for players in the global cell expansion market, over the forecast period.

Development of new technologies in cell expansion is expected to offer lucrative growth opportunities for players in the global cell expansion market. For instance, in March 2022, WuXi Advanced Therapies, a wholly owned subsidiary of WuXi AppTec, announced the launch of Tetracycline-Enabled Self-Silencing Adenovirus (TESSA), which is a state-of-the-art novel process for scalable manufacture of transfection-free adeno-associated virus (AAV) at Good Manufacturing Practice (GMP) grade. TESSA, is developed by OXGENE in the U.K., a WuXi Advanced Therapies firm, which will speed up AAV manufacture and lower the cost of cell and gene therapies manufacturing, allowing worldwide customers to offer more accessible ground-breaking treatments to patients as rapidly as feasible.

Key players are involved in launching of a new medium for the expansion and maintenance of cells is expected to drive the growth of global cell expansion market, over the forecast period.

Key players are involved in launching of a new medium for the expansion and maintenance of cells is expected to drive the growth of global cell expansion market. For instance, in September 2021, Bio-Techne Corporation, which develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostic, and bioprocessing markets, announced the launch of a new medium for the expansion and maintenance of induced pluripotent stem cells (iPSCs), which can be used in both research and translational workflows. The ExCellerate iPSC Expansion Medium is the newest addition to Bio-Techne's regenerative medicine portfolio.

Global Cell Expansion Market – Restraints

Animal and human cells are also utilized to evaluate medicines for in vivo toxicity and pharmacokinetics in animals and humans. Furthermore, stem cell research uses human embryos for clinical purposes, which frequently results in the killing of human embryos.  Stringent restrictions have been created by ethical authorities such as The Human Tissue Authority (HTA), the Human Fertilization and Embryology Authority (HFEA), etc. in numerous nations across the world to supervise these operations. For instance, prohibitions under the 1990 Act on Human Embryo Research by the Human Fertilization and Embryology Authority includes, keeping or using an embryo after the appearance of the primitive streak, or after 14 days whichever is the earlier, placing an embryo in a non-human animal, placing non-human gametes or embryos in a woman, replacing a nucleus of a cell of an embryo with a nucleus taken from the cell of another person, another embryo, or a subsequent development of an embryo, altering the genetic structure of any cell while it forms part of an embryo.

Global Cell Expansion Market – Regional Analysis

On the basis of region, the global cell expansion market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa

Among regions, North America cell expansion market is expected to hold a dominant position during the forecast period, owing to the increasing acquisition by market players of cell and gene therapy manufacturing facilities in the region. For instance, in July 2021, AGC Biologics, a major global biopharmaceutical contract development and manufacturing organization (CDMO), signed a purchase agreement with Novartis Gene Therapies, a division of Novartis AG to acquire a state-of-the-art cell and gene therapy commercial manufacturing facility in Longmont, Colorado, U.S. The facility will provide AGC Biologics with significant extra capacity and space, pending full due diligence, to continue to develop its end-to-end Cell and Gene Therapy (C&GT) offering, assuring supply security for current and future C&GT clients.

Furthermore, Europe is expected to exhibit significant growth in the cell expansion market, owing to increasing facility expansion and investment in cell and gene therapy manufacturing by market players in this region. For instance, in March 2021, GSK, a science-led global healthcare company, announced the agreement with Cell and Gene Therapy Catapult, a non-profit organization dedicated to the improvement of cell and gene therapies through creativity and technology, to expand its clinical trial manufacturing capacity for cell and gene therapy at the Cell and Gene Therapy Catapult facility in Stevenage, U.K.

Figure 2. Global Cell Expansion Market Share, By Product, 2024

To learn more about this report, request a free sample copy

Recent Developments

In December 2023, FUJIFILM Corporation, a multinational conglomerate, announced a USD 200 million investment in two subsidiaries to dramatically enhance global cell therapy contract development and manufacturing (CDMO) capabilities. The investment would allow Fujifilm to support the growing cell therapy business, which is expected to increase by more than 30% per year from USD 3.3 billion in FY2022.

In February 2023, Terumo Blood and Cell Technologies, a medical technology company, presented data from its Quantum Flex Cell Expansion System for the first time at a major conference, revealing how its hollow-fiber perfusion technique speeds up T-cell treatment development in a range of bioreactors. Terumo BCT scientists reported the results of several T-cell expansion runs at the CAR-TCR Summit Europe in London, with a 60% to 70% reduction in media utilization and 8.7 to 9.6 population doublings over the course of 8 days.

In September 2021, Bio-Techne Corporation, a company that develops, manufactures, and sells life science reagents, announced the release of a novel medium for the multiplication and preservation of induced pluripotent stem cells (iPSCs) for use in both research and translation workflows. The ExCellerate iPSC Expansion Medium is the latest addition to Bio-Techne's extensive Regenerative Medicine product and service range. It is intended to integrate easily with their stem cell process solutions, which include cell isolation, reprogramming, genome engineering, cell growth, differentiation, and characterization.

In March 2021, AGC Biologics, a major global biopharmaceutical contract development and manufacturing organization (CDMO), announced intentions to expand its Cell and Gene Therapy Center of Excellence in Milan, increasing capacity and implementing viral vector suspension capabilities. With this expansion, AGC Biologics will add two new floors to the suite and upgrade the equipment on the current floor. The new facilities are set to go fully operational in 2022.

Global Cell Expansion Market – Competitive Landscape

Major players operating in the global cell expansion market include Becton, Dickinson and Company, Sartorius AG, Merck KGaA, Corning, Inc., Eppendorf SE, Lonza Group AG, PromoCell, Danaher, Thermo Fisher Scientific, HiMedia Laboratories, STEMCELL Technologies Inc., REPROCELL Inc., Bio-Techne, Valiant Co., Ltd., Miltenyi Biotec, Biologos, Cyagen US Inc.